
Eli Lilly and Co
NYSE:LLY

Intrinsic Value
The intrinsic value of one
LLY
stock under the Base Case scenario is
230.5
USD.
Compared to the current market price of 339.1 USD,
Eli Lilly and Co
is
Overvalued by 32%.
The Intrinsic Value is calculated as the average of the two valuation methods:

Fundamental Analysis
LLY Profitability Score
Profitability Due Diligence
Eli Lilly and Co's profitability score is 71/100. The higher the profitability score, the more profitable the company is.
Score
Eli Lilly and Co's profitability score is 71/100. The higher the profitability score, the more profitable the company is.
LLY Solvency Score
Solvency Due Diligence
Eli Lilly and Co's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Eli Lilly and Co's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Balance Sheet Decomposition
Eli Lilly and Co
LLY Capital Structure
Eli Lilly and Co
Market Capitalization | 322B USD | |
Total Debt | 14.1B USD | |
Minority Interest | 95.8M USD | |
Preferred Equity | 0 USD | |
Cash and Equivalents | 2.6B USD | |
Short-Term Investments | 125M USD | |
Enterprise Value | 334B USD |
Wall St
Price Targets
LLY Price Targets Summary
Eli Lilly and Co
According to Wall Street analysts, the average 1-year price target for
LLY
is 397.31 USD
with a low forecast of 270.68 USD and a high forecast of 462 USD.
Competitive Landscape
LLY Competitors
Eli Lilly and Co
LLY Suppliers & Customers
Eli Lilly and Co
Eli Lilly and Co has 88 key suppliers from 13 countries and 14 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Biotechnology industry.
Eli Lilly and Co has 42 key customers from 8 countries and 6 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Biotechnology industry.
Ownership
LLY Insider Trading
Buy and sell transactions by insiders
During the last 12 months Eli Lilly and Co insiders bought 249k USD , and sold 1.4B USD worth of shares. The last transaction was made on Feb 6, 2023 by Lilly Endowment Inc (10 percent owner), who sold 18.3M USD worth of LLY shares.
Shareholder Return
LLY Price
Eli Lilly and Co
Average Annual Return | 40.76% |
Standard Deviation of Annual Returns | 22.21% |
Max Drawdown | -12% |
Market Capitalization | 322B USD |
Shares Outstanding | 950 177 984 |
Percentage of Shares Shorted | 0.71% |
Company Profile

Country
Industry
Market Cap
Dividend Yield
Description
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 35,000 full-time employees. The firm is engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products across the world. The firm's diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta and Trulicity. Its oncology products include Alimta, Cyramza, Erbitux, Retevmo, Tyvyt and Verzenio. The firm's immunology products consist of Olumiant and Taltz. Its neuroscience products include Cymbalta, Emgality, Reyvow and Zyprexa. Its other therapies consist of Bamlanivimab, etesevimab, Cialis and Forteo. The firm manufactures and distributes its products through facilities in the United States, including Puerto Rico, and about eight other countries. Its products are sold in approximately 120 countries. Its subsidiaries include Acanthas Pharma, Inc., Alnara Pharmaceuticals, Inc., ARMO Biosciences, Inc., and Avid Radiopharmaceuticals, Inc., among others.
Contact
IPO
Employees
Officers
The intrinsic value of one
LLY
stock under the Base Case scenario is
230.5
USD.
Compared to the current market price of 339.1 USD, Eli Lilly and Co is Overvalued by 32%.